跳至主要内容
临床试验/EUCTR2011-006272-39-ES
EUCTR2011-006272-39-ES进行中(未招募)不适用

CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY AND ECONOMIC IMPACT OF REDUCING DOSES OF DARUNAVIR IN PATIENTS INFECTED WITH HIV TREATED WITH DARUNAVIR / RITONAVIR ONCE A DAY

Fundació Lluita contra la SIDA0 个研究点开始时间: 2012年2月10日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Treatment stable with darunavir / ritonavir 800/100 mg qd plus two nucleoside analogs transcriptase inhibitors for at least 4 weeks.
  • - HIV viral load in plasma <50 copies / mL for at least 12 weeks.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 112
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - AIDS-defining disease in the previous 4 weeks.
  • -Virologic failure history previous antiretroviral treatment regimens that included protease inhibitor drugs.
  • - Presence of darunavir resistance mutations documented in previous genotypes.

研究者

发起方
Fundació Lluita contra la SIDA

相似试验